85 related articles for article (PubMed ID: 28993342)
1.
Osada T; Kaneko K; Gwin WR; Morse MA; Hobeika A; Pogue BW; Hartman ZC; Hughes PF; Haystead T; Lyerly HK
Clin Cancer Res; 2017 Dec; 23(24):7531-7542. PubMed ID: 28993342
[No Abstract] [Full Text] [Related]
2. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
3. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
5. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
6. HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.
Osada T; Crosby EJ; Kaneko K; Snyder JC; Ginzel JD; Acharya CR; Yang XY; Polascik TJ; Spasojevic I; Nelson RC; Hobeika A; Hartman ZC; Neckers LM; Rogatko A; Hughes PF; Huang J; Morse MA; Haystead T; Lyerly HK
Mol Cancer Ther; 2022 Jan; 21(1):217-226. PubMed ID: 34675120
[TBL] [Abstract][Full Text] [Related]
7. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
8. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer.
Kosinsky RL; Helms M; Zerche M; Wohn L; Dyas A; Prokakis E; Kazerouni ZB; Bedi U; Wegwitz F; Johnsen SA
Cell Death Dis; 2019 Dec; 10(12):911. PubMed ID: 31801945
[TBL] [Abstract][Full Text] [Related]
9. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Shee K; Wells JD; Ung M; Hampsch RA; Traphagen NA; Yang W; Liu SC; Zeldenrust MA; Wang L; Kalari KR; Yu J; Boughey JC; Demidenko E; Kettenbach AN; Cheng C; Goetz MP; Miller TW
Clin Cancer Res; 2020 Jan; 26(1):159-170. PubMed ID: 31558472
[TBL] [Abstract][Full Text] [Related]
10. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
[TBL] [Abstract][Full Text] [Related]
11. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
12. Short-hairpin RNA-mediated Heat shock protein 90 gene silencing inhibits human breast cancer cell growth in vitro and in vivo.
Zuo K; Li D; Pulli B; Yu F; Cai H; Yuan X; Zhang X; Lv Z
Biochem Biophys Res Commun; 2012 May; 421(2):396-402. PubMed ID: 22521890
[TBL] [Abstract][Full Text] [Related]
13. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
Lee CH; Hong HM; Chang YY; Chang WW
Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
[TBL] [Abstract][Full Text] [Related]
15. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
16. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
18. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic and Therapeutic Potential of Membrane HSP90].
Vacek O; Pastorek M; Durech M; Vojtěšek B; Müller P
Klin Onkol; 2017; 30(Supplementum1):191-194. PubMed ID: 28471204
[TBL] [Abstract][Full Text] [Related]
20. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]